Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $191.1 million.

  • Arcutis Biotherapeutics' Cash & Current Investments fell 4219.89% to $191.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.1 million, marking a year-over-year decrease of 4219.89%. This contributed to the annual value of $228.0 million for FY2024, which is 1615.02% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Cash & Current Investments is $191.1 million, which was down 4219.89% from $190.8 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Cash & Current Investments' 5-year high stood at $477.0 million during Q3 2022, with a 5-year trough of $190.8 million in Q2 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $332.4 million (2023), whereas its average is $322.4 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Cash & Current Investments skyrocketed by 9359.34% in 2021 and then tumbled by 5238.35% in 2023.
  • Arcutis Biotherapeutics' Cash & Current Investments (Quarter) stood at $387.1 million in 2021, then rose by 5.82% to $409.6 million in 2022, then crashed by 33.63% to $271.9 million in 2023, then decreased by 16.15% to $228.0 million in 2024, then dropped by 16.18% to $191.1 million in 2025.
  • Its last three reported values are $191.1 million in Q3 2025, $190.8 million for Q2 2025, and $198.1 million during Q1 2025.